VivoSim Labs, Inc. (VIVS): Operating Income
-$11.49M
Year ended 2026-03-31
-$11.33M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | -$11.49M | n/m | 2026-07-14, From 2025-04-01 |
| 2025-03-31 | -$12.62M | n/m | 2026-07-14, From 2024-04-01 |
| 2024-03-31 | -$15.09M | n/m | 2025-06-05, From 2023-04-01 |
| 2023-03-31 | -$17.73M | n/m | 2024-05-31, From 2022-04-01 |
| 2022-03-31 | -$11.48M | n/m | 2023-07-14, From 2021-04-01 |
| 2021-03-31 | -$16.83M | n/m | 2022-06-10, From 2020-04-01 |
| 2020-03-31 | -$21.48M | n/m | 2021-06-15, From 2019-04-01 |
| 2019-03-31 | -$27.27M | n/m | 2020-05-28, From 2018-04-01 |
| 2018-03-31 | -$35.27M | n/m | 2019-06-03, From 2017-04-01 |
| 2017-03-31 | -$38.58M | n/m | 2018-05-31, From 2016-04-01 |
| 2016-03-31 | -$38.64M | n/m | 2018-05-31, From 2015-04-01 |
| 2015-03-31 | -$30.30M | n/m | 2017-06-07, From 2014-04-01 |
| 2014-03-31 | -$20.65M | n/a | 2016-06-09, From 2013-04-01 |
| No annual figure between 2012-12-31 and 2014-03-31. | |||
| 2012-12-31 | -$9.32M | n/m | 2015-06-09, From 2012-01-01 |
| 2011-12-31 | -$2.31M | n/a | 2014-06-10, From 2011-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| VivoSim Labs, Inc. (VIVS) | 2026-03-31 | -$11.49M | n/m |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | -$13.36M | n/m |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | -$77.63M | n/m |
| AIM ImmunoTech Inc. (AIM) | 2025-12-31 | -$11.66M | n/m |
| Inmune Bio, Inc. (INMB) | 2025-12-31 | -$47.38M | n/m |
| Entera Bio Ltd. (ENTX) | 2025-12-31 | -$11.53M | n/m |
| Cardiff Oncology, Inc. (CRDF) | 2025-12-31 | -$48.96M | n/m |
| Senti Biosciences Holdings, Inc. (SNTI) | 2025-12-31 | -$68.78M | n/m |
| ImageneBio, Inc. (IMA) | 2025-12-31 | -$48.45M | n/m |
Compare VIVS, ZIVO, ATYR, AIM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗